https://medesis-pharma.17pixel.com/technology/summary-of-technology/2017-06-21T16:46:16+02:00https://medesis-pharma.17pixel.com/technology/intellectual-property/2017-07-04T14:43:28+02:00https://medesis-pharma.17pixel.com/technology/multiple-drug-applications-of-technology/2017-10-06T07:36:03+02:00https://medesis-pharma.17pixel.com/technology/advantages/2017-06-20T18:31:15+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/drugs-for-the-protection-of-populations-exposed-to-a-nuclear-accident/2017-11-08T17:01:17+01:00https://medesis-pharma.17pixel.com/clinical-stage-products/drug-to-treat-type-2-diabetes/2017-09-28T16:24:54+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/huntingtons-disease/2017-10-05T16:04:49+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/alzheimers-disease/2020-03-30T16:25:24+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/drug-to-treat-neurodegenerative-diseases/2017-06-20T11:33:58+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/nuclear-radioprotection-drug/2020-03-30T16:35:01+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/nuclear-decorporation-drugs/2017-10-05T16:12:11+02:00https://medesis-pharma.17pixel.com/research/oncology-personalized-treatment-of-cancers/2017-10-05T16:58:27+02:00https://medesis-pharma.17pixel.com/research/protection-of-healthy-tissues-in-cancer-radiotherapy/2017-10-05T17:07:46+02:00https://medesis-pharma.17pixel.com/research/treatment-of-huntingtons-disease/2017-10-04T17:20:41+02:00https://medesis-pharma.17pixel.com/investors/financing-history-an-atypical-financing-of-the-company/2017-06-24T13:10:19+02:00https://medesis-pharma.17pixel.com/investors/become-shareholders/2017-06-26T12:02:17+02:00https://medesis-pharma.17pixel.com/investors/shareholder-club/2017-06-22T11:45:34+02:00https://medesis-pharma.17pixel.com/banner-in-one/we-develop-a-drug-for-children-to-eliminate-cesium-following-a-nuclear-accident/2017-06-27T10:12:53+02:00https://medesis-pharma.17pixel.com/banner-in-one/we-develop-drugs-to-treat-populations-contaminated-during-a-nuclear-accident/2017-06-27T10:09:39+02:00https://medesis-pharma.17pixel.com/banner-in-one/improve-the-lives-of-patients-suffering-from-alzheimers-disease/2017-06-27T10:08:28+02:00https://medesis-pharma.17pixel.com/banner-in-one/preserving-the-brain-in-neurodegenerative-diseases/2017-06-27T10:07:32+02:00https://medesis-pharma.17pixel.com/banner-in-one/breakthrough-technology-to-optimize-drug-administration-and-efficacy/2017-06-27T10:06:14+02:00https://medesis-pharma.17pixel.com/banner-in-one/we-develop-new-drugs-to-preserve-life/2017-06-20T19:20:50+02:00https://medesis-pharma.17pixel.com/in-one/cesium-decorporation/2017-06-23T16:54:00+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/aonys-technology/2017-10-10T15:14:31+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/nuclear-decorporation-drugs-cesium-decorporation/2017-10-05T16:31:29+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/pipeline/2017-10-04T17:48:41+02:00https://medesis-pharma.17pixel.com/non-classe/bace1-inhibition-translational-psychiatry-2017/2017-10-04T11:23:39+02:00https://medesis-pharma.17pixel.com/news-publications/press-news/a-treatment-for-alzheimers-disease/2017-10-17T16:55:32+02:00https://medesis-pharma.17pixel.com/news-publications/press-news/747/2017-10-17T17:00:37+02:00https://medesis-pharma.17pixel.com/non-classe/systemic-delivery-of-p42-peptide-english/2017-10-04T10:19:39+02:00https://medesis-pharma.17pixel.com/non-classe/in-situ-synthesis-of-prussian-blue-particles/2017-10-03T09:44:12+02:00https://medesis-pharma.17pixel.com/non-classe/formulation-of-lithium-loaded-microemulsion-system_en/2017-10-03T11:08:39+02:00https://medesis-pharma.17pixel.com/non-classe/development-of-pharmaceutical-clear-gel-based-on-peceol_en/2017-10-03T14:48:05+02:00https://medesis-pharma.17pixel.com/non-classe/water-solubilization-capacity-of-pharmaceutical-microemulsions_en/2017-10-03T16:06:18+02:00https://medesis-pharma.17pixel.com/non-classe/phase-behavior-of-reverse-microemulsions-based-on-peceol_en/2017-10-03T16:45:27+02:00https://medesis-pharma.17pixel.com/non-classe/systemic-delivery-of-sirna-down-regulates-brain-prion-protein_en/2017-10-04T09:16:41+02:00https://medesis-pharma.17pixel.com/non-classe/np03-a-novel-low-dose-lithium-formulation-is-neuroprotective-in-the-yac128-mouse_en/2017-10-04T11:08:13+02:00https://medesis-pharma.17pixel.com/news-publications/press-news/alzheimer-what-if-medesis-pharma-had-the-right-key/2017-11-08T16:41:23+01:00https://medesis-pharma.17pixel.com/news-publications/press-news/medesis-pharma-and-transgene-collaborate-to-explore-the-contribution-of-the-aonys-platform-to-oncolytic-virotherapies/2019-07-12T11:19:33+02:00https://medesis-pharma.17pixel.com/news-publications/press-news/medesis-pharma-propose-ses-nanoemulsions-de-nanomanganese-pour-traiter-le-covid-19/2020-03-27T18:46:50+01:00https://medesis-pharma.17pixel.com/in-one/covid-teatments-using-drug-delivery-technology/2020-03-30T16:28:16+02:00https://medesis-pharma.17pixel.com/banner-in-one/covid-19-treatments-using-drug-delivery-technology/2020-03-31T17:41:09+02:00https://medesis-pharma.17pixel.com/clinical-stage-products/viral-diseases/2020-11-25T14:06:09+01:00https://medesis-pharma.17pixel.com/preclinical-stage-product/transgene/2020-11-25T14:07:30+01:00https://medesis-pharma.17pixel.com/clinical-stage-products/nanomanganese/2020-11-25T14:08:35+01:00https://medesis-pharma.17pixel.com/clinical-stage-products/nanosirna/2020-11-25T14:09:15+01:00